vs
ANGIODYNAMICS INC（ANGO）与iRhythm Holdings, Inc.（IRTC）财务数据对比。点击上方公司名可切换其他公司
iRhythm Holdings, Inc.的季度营收约是ANGIODYNAMICS INC的2.6倍（$208.9M vs $79.4M）。iRhythm Holdings, Inc.净利率更高（2.7% vs -8.0%，领先10.7%）。iRhythm Holdings, Inc.同比增速更快（27.1% vs 9.0%）。iRhythm Holdings, Inc.自由现金流更多（$14.5M vs $4.2M）。过去两年iRhythm Holdings, Inc.的营收复合增速更高（25.8% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
iRhythm Holdings是一家专注于心脏护理领域的数字医疗企业，开发可穿戴动态心脏监测设备及配套AI分析工具，主要服务美国市场的医疗机构与患者，帮助检测房颤等心律异常病症，为临床诊断提供可靠的数据支持。
ANGO vs IRTC — 直观对比
营收规模更大
IRTC
是对方的2.6倍
$79.4M
营收增速更快
IRTC
高出18.1%
9.0%
净利率更高
IRTC
高出10.7%
-8.0%
自由现金流更多
IRTC
多$10.3M
$4.2M
两年增速更快
IRTC
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $208.9M |
| 净利润 | $-6.3M | $5.6M |
| 毛利率 | 56.4% | 70.9% |
| 营业利润率 | -7.7% | 1.1% |
| 净利率 | -8.0% | 2.7% |
| 营收同比 | 9.0% | 27.1% |
| 净利润同比 | 40.9% | 518.5% |
| 每股收益（稀释后） | $-0.15 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOIRTC
| Q4 25 | $79.4M | $208.9M | ||
| Q3 25 | $75.7M | $192.9M | ||
| Q2 25 | $80.2M | $186.7M | ||
| Q1 25 | $72.0M | $158.7M | ||
| Q4 24 | $72.8M | $164.3M | ||
| Q3 24 | $67.5M | $147.5M | ||
| Q2 24 | $71.0M | $148.0M | ||
| Q1 24 | $75.2M | $131.9M |
净利润ANGOIRTC
| Q4 25 | $-6.3M | $5.6M | ||
| Q3 25 | $-10.9M | $-5.2M | ||
| Q2 25 | $-6.0M | $-14.2M | ||
| Q1 25 | $-4.4M | $-30.7M | ||
| Q4 24 | $-10.7M | $-1.3M | ||
| Q3 24 | $-12.8M | $-46.2M | ||
| Q2 24 | $-13.4M | $-20.1M | ||
| Q1 24 | $-187.7M | $-45.7M |
毛利率ANGOIRTC
| Q4 25 | 56.4% | 70.9% | ||
| Q3 25 | 55.3% | 71.1% | ||
| Q2 25 | 52.7% | 71.2% | ||
| Q1 25 | 54.0% | 68.8% | ||
| Q4 24 | 54.8% | 70.0% | ||
| Q3 24 | 54.4% | 68.8% | ||
| Q2 24 | 54.3% | 69.9% | ||
| Q1 24 | 47.7% | 66.3% |
营业利润率ANGOIRTC
| Q4 25 | -7.7% | 1.1% | ||
| Q3 25 | -14.1% | -4.4% | ||
| Q2 25 | -7.2% | -10.0% | ||
| Q1 25 | -13.9% | -20.5% | ||
| Q4 24 | -15.2% | -2.5% | ||
| Q3 24 | -19.4% | -34.1% | ||
| Q2 24 | -20.4% | -15.5% | ||
| Q1 24 | -265.9% | -28.9% |
净利率ANGOIRTC
| Q4 25 | -8.0% | 2.7% | ||
| Q3 25 | -14.4% | -2.7% | ||
| Q2 25 | -7.5% | -7.6% | ||
| Q1 25 | -6.1% | -19.3% | ||
| Q4 24 | -14.7% | -0.8% | ||
| Q3 24 | -19.0% | -31.3% | ||
| Q2 24 | -18.9% | -13.6% | ||
| Q1 24 | -249.7% | -34.6% |
每股收益（稀释后）ANGOIRTC
| Q4 25 | $-0.15 | $0.18 | ||
| Q3 25 | $-0.26 | $-0.16 | ||
| Q2 25 | $-0.15 | $-0.44 | ||
| Q1 25 | $-0.11 | $-0.97 | ||
| Q4 24 | $-0.26 | $-0.03 | ||
| Q3 24 | $-0.31 | $-1.48 | ||
| Q2 24 | $-0.35 | $-0.65 | ||
| Q1 24 | $-4.67 | $-1.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $583.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $152.7M |
| 总资产 | $269.7M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGOIRTC
| Q4 25 | $41.6M | $583.8M | ||
| Q3 25 | $38.8M | $565.2M | ||
| Q2 25 | $55.9M | $545.5M | ||
| Q1 25 | $44.8M | $520.6M | ||
| Q4 24 | $54.1M | $535.6M | ||
| Q3 24 | $55.0M | $522.0M | ||
| Q2 24 | $76.1M | $561.5M | ||
| Q1 24 | $78.5M | $569.1M |
总债务ANGOIRTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGOIRTC
| Q4 25 | $176.3M | $152.7M | ||
| Q3 25 | $178.9M | $121.9M | ||
| Q2 25 | $183.0M | $103.7M | ||
| Q1 25 | $185.9M | $86.7M | ||
| Q4 24 | $186.8M | $90.9M | ||
| Q3 24 | $196.6M | $71.8M | ||
| Q2 24 | $205.6M | $99.2M | ||
| Q1 24 | $218.7M | $90.3M |
总资产ANGOIRTC
| Q4 25 | $269.7M | $1.0B | ||
| Q3 25 | $265.6M | $995.2M | ||
| Q2 25 | $280.1M | $964.0M | ||
| Q1 25 | $285.4M | $926.1M | ||
| Q4 24 | $291.6M | $931.4M | ||
| Q3 24 | $293.6M | $909.7M | ||
| Q2 24 | $317.7M | $919.2M | ||
| Q1 24 | $324.8M | $909.8M |
负债/权益比ANGOIRTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $14.5M |
| 自由现金流率自由现金流/营收 | 5.3% | 6.9% |
| 资本支出强度资本支出/营收 | 0.5% | 5.6% |
| 现金转化率经营现金流/净利润 | — | 4.70× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $34.5M |
8季度趋势，按日历期对齐
经营现金流ANGOIRTC
| Q4 25 | $4.7M | $26.2M | ||
| Q3 25 | $-15.9M | $34.9M | ||
| Q2 25 | $18.8M | $27.7M | ||
| Q1 25 | $-13.2M | $-7.9M | ||
| Q4 24 | $2.5M | $19.2M | ||
| Q3 24 | $-18.3M | $24.3M | ||
| Q2 24 | $5.0M | $11.8M | ||
| Q1 24 | $-12.5M | $-52.0M |
自由现金流ANGOIRTC
| Q4 25 | $4.2M | $14.5M | ||
| Q3 25 | $-16.6M | $20.1M | ||
| Q2 25 | $18.0M | $17.3M | ||
| Q1 25 | $-15.0M | $-17.3M | ||
| Q4 24 | $1.7M | $12.4M | ||
| Q3 24 | $-19.3M | $15.5M | ||
| Q2 24 | $4.4M | $3.4M | ||
| Q1 24 | $-13.1M | $-61.8M |
自由现金流率ANGOIRTC
| Q4 25 | 5.3% | 6.9% | ||
| Q3 25 | -22.0% | 10.4% | ||
| Q2 25 | 22.5% | 9.3% | ||
| Q1 25 | -20.8% | -10.9% | ||
| Q4 24 | 2.3% | 7.5% | ||
| Q3 24 | -28.7% | 10.5% | ||
| Q2 24 | 6.2% | 2.3% | ||
| Q1 24 | -17.5% | -46.8% |
资本支出强度ANGOIRTC
| Q4 25 | 0.5% | 5.6% | ||
| Q3 25 | 1.0% | 7.7% | ||
| Q2 25 | 1.0% | 5.6% | ||
| Q1 25 | 2.5% | 5.9% | ||
| Q4 24 | 1.1% | 4.2% | ||
| Q3 24 | 1.6% | 6.0% | ||
| Q2 24 | 0.8% | 5.7% | ||
| Q1 24 | 0.8% | 7.4% |
现金转化率ANGOIRTC
| Q4 25 | — | 4.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
